|
|
|
| |
Brought to you by
|
|
| |
The latest Biotech News and Views |
|
|
|
Brought to you by
|
|
| |
Good morning. The thyroid eye disease (TED) market is getting increasingly crowded. Amgen's Tepezza is already approved, while late-stage assets from Viridian, argenx, Biohaven, Immunovant, and Sanofi are racing toward the market. Now, new kid on the block, Ethyreal Bio, has just exited stealth with $101 million to join the race. May the best one win.
— Joachim E. |
|
|
| SNAPSHOT |
| Parabilis shatters biotech IPO records with a $670 million debut amid a booming 2026 market |
 |
| Parabilis Medicines raised $670 million in its IPO, making it the largest-ever public stock offering by a venture-backed biotech company and continuing a surge of large biotech listings in 2026. |
| Why it matters: The record-breaking IPO signals strong investor appetite for innovative drug developers, especially companies tackling historically "undruggable" disease targets. The strong fundraising environment gives biotechs greater resources to advance expensive late-stage clinical trials. |
| Backstory: Founded by serial biotech entrepreneur Gregory Verdine, Parabilis (formerly FogPharma) has spent years developing "Helicons", a new class of helix-shaped peptide medicines designed to enter cells and target cancer-driving proteins that traditional drugs have struggled to reach. The company previously raised more than $800 million from private investors and later rebranded as Parabilis. Former Johnson & Johnson research executive Mathai Mammen now serves as CEO. |
| Big picture: Parabilis' IPO highlights a dramatic rebound in biotech public markets. In 2026, 12 drug companies have gone public in the U.S., raising more than $4.1 billion combined, with a median IPO size of roughly $300 million; more than double the typical biotech IPO proceeds from the previous year. The company's record surpasses Moderna's $604 million 2018 IPO and Kailera Therapeutics' $625 million offering earlier in 2026. |
| Zoom in: Parabilis' lead drug candidate, zolucatetide, targets the beta-catenin signaling pathway, which is involved in millions of cancer cases. Early studies suggest promise in treating desmoid tumors, and the company believes the therapy could be more effective and safer than existing options. |
| What's next: Parabilis plans to launch a Phase 3 clinical trial of zolucatetide for desmoid tumors in the first half of 2027. The company is also expanding testing into other cancers and advancing earlier-stage programs targeting prostate cancer. |
|
|
| SNIPPETS |
| What's happening in biotech today? |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclaimer: The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical or AZoNetwork. |
|
|
|
| |
|
|
|
|
|
|
|
